S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory

Ardelyx (ARDX) Stock Forecast & Price Target

$7.06
-0.31 (-4.21%)
(As of 04/12/2024 ET)

Ardelyx Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$12.56
77.94% Upside
High Forecast$15.00
Average Forecast$12.56
Low Forecast$8.50
TypeCurrent Forecast
4/14/23 to 4/13/24
1 Month Ago
3/15/23 to 3/14/24
3 Months Ago
1/14/23 to 1/14/24
1 Year Ago
4/14/22 to 4/14/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$12.56$12.36$11.92$6.00
Predicted Upside77.94% Upside80.68% Upside84.49% Upside190.95% Upside
Get Ardelyx Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

ARDX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ardelyx Stock vs. The Competition

TypeArdelyxMedical CompaniesS&P 500
Consensus Rating Score
3.11
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside77.94% Upside796.20% Upside10.17% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/5/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Ruiz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/5/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$14.00+95.53%
2/23/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$12.00 ➝ $15.00+69.88%
2/23/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$13.00+47.39%
1/12/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
1/10/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$9.00 ➝ $14.00+56.25%
1/9/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetStrong-Buy ➝ Strong-Buy$12.00 ➝ $15.00+83.37%
11/1/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$9.00 ➝ $11.00+184.24%
8/3/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$7.50 ➝ $8.50+110.40%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:57 PM ET.

ARDX Price Target - Frequently Asked Questions

What is Ardelyx's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Ardelyx stock is Buy based on the current 8 buy ratings and 1 strong buy rating for ARDX. The average twelve-month price prediction for Ardelyx is $12.56 with a high price target of $15.00 and a low price target of $8.50. Learn more on ARDX's analyst rating history.

Do Wall Street analysts like Ardelyx more than its competitors?

Analysts like Ardelyx more than other Medical companies. The consensus rating for Ardelyx is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how ARDX compares to other companies.

Does Ardelyx's stock price have much upside?

According to analysts, Ardelyx's stock has a predicted upside of 82.54% based on their 12-month stock forecasts.

What analysts cover Ardelyx?

Ardelyx has been rated by Leerink Partnrs, Piper Sandler, SVB Leerink, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ARDX) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners